Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchRegdanvimabRegdanvimab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

    
  
Regdanvimab for COVID-19
11 studies from 118 scientists
7,430 patients in 1 country
Statistically significant lower risk for mortality, hospitalization, progression, and recovery.
10 studies from 7 independent teams (all from the same country) show significant improvements.
COVID-19 Regdanvimab studies. Jul 2024. c19early.org
0 0.5 1 1.5+ All studies 63% With exclusions 64% Mortality 63% Hospitalization 15% Recovery 41% Viral clearance 19% RCTs 10% Early 62% Late 86% Favorsregdanvimab Favorscontrol
Home   Post   Share   @CovidAnalysis   Meta AnalysisMeta   Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2, BA.4, BA.5 Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi. mAb use may create new variants that spread globally Focosi, Leducq, and may be associated with prolonged viral loads, clinical deterioration, and immune escape Choudhary, Günther, Leducq. Regdanvimab was adopted in 27 countries. Submit updates/corrections. Summary.
Jul 20
Covid Analysis Regdanvimab for COVID-19: real-time meta analysis of 11 studies
Statistically significant lower risk is seen for mortality, hospitalization, progression, and recovery. 10 studies from 7 independent teams (all from the same country) show significant improvements. Meta analysis using the most serious ou..
May 23
Lee et al., Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfae069.1573 Effectiveness of regdanvimab on clinical outcomes in COVID-19 infected patients on hemodialysis
59% lower mortality (p=0.002). Retrospective 230 hemodialysis patients with COVID-19, showing lower mortality with regdanvimab. Details of the adjusted results are not provided.
Apr 12
Hwang et al., Infectious Diseases and Therapy, doi:10.1007/s40121-024-00971-w Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study
83% lower mortality (p=0.12), 33% lower ICU admission (p=0.49), and 55% lower need for oxygen therapy (p=0.01). PSM retrospective 378 hospitalized COVID-19 patients in Korea showing lower progression with regdanvimab treatment.
Jan 23
Kee et al., Kidney Research and Clinical Practice, doi:10.23876/j.krcp.23.137 Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis
Retrospective 230 hospitalized COVID-19 patients on hemodialysis, reporting lower mortality with regdanvimab treatment. The results are conflicting, with for example the text reporting HR 0.28 for regdanvimab in multivariable analysis, ho..
Nov 10
2023
Noh et al., Medicine, doi:10.1097/MD.0000000000035987 Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
Retrospective 101 hospitalized COVID-19 patients in South Korea examining outcomes with the monoclonal antibody treatment regdanvimab, comparing 31 patients during the delta variant outbreak period to 49 patients with pre-delta variants. ..
Sep 28
2023
Pochtovyi et al., Vaccines, doi:10.3390/vaccines11101533 In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
In Vitro study showing sharply reduced neutralization of SARS-CoV-2 variants XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1 with monoclonal antibodies cilgavimab, tixagevimab, imdevimab, etsevimab, casirivim..
Sep 27
2023
Haars et al., Microorganisms, doi:10.3390/microorganisms11102417 Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023
Analysis of 7,950 SARS-CoV-2 samples from central Sweden collected between March 2022 and May 2023 tracking the prevalence of omicron sublineages and mutations in the spike protein conferring resistance to monoclonal antibodies over time...
May 15
2023
Kim et al., Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2023.1192512 Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
51% lower progression (p=0.0002) and 32% lower need for oxygen therapy (p<0.0001). Retrospective 2,214 mild/moderate COVID-19 patients in South Korea, 1,095 treated with regdanivimab, showing lower oxygen requirements and lower progression to severe disease with treatment in the overall cohort, but not within the delta ..
Jan 6
2023
Jang et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.12.035 Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
12% shorter hospitalization (p<0.0001), 49% lower need for oxygen therapy (p<0.0001), and 68% higher hospital discharge (p<0.0001). Retrospective 722 hospitalized mild-to-moderate COVID-19 patients in Korea showing lower risk of disease progression with regdanvimab treatment.
Aug 21
2022
Moench et al., medRxiv, doi:10.1101/2022.08.17.22278748 A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19
Phase 1 study of 23 healthy adults showing inhaled regdanvimab (IN-006) was well tolerated after single doses of 30mg and 90mg and 7 daily 90mg doses. High concentrations were achieved in nasal fluids and serum, over 1000 times the inhibi..
Aug 8
2022
Kim et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac406 A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
86% lower ventilation (p=0.25), 91% lower ICU admission (p=0.06), 69% lower need for oxygen therapy (p<0.0001), and 69% lower hospitalization (p<0.0001). RCT 1,315 outpatients in South Korea, showing lower progression and improved recovery with regdanvimab.
May 16
2022
Jang et al., Current Therapeutic Research, doi:10.1016/j.curtheres.2022.100675 Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
60% lower need for oxygen therapy (p<0.0001), 44% higher hospital discharge (p=0.03), and 13% shorter hospitalization (p=0.003). Retrospective 317 hospitalized mild-moderate COVID-19 patients in South Korea showing significantly lower rates of oxygen desaturation (SpO2 <94%) at 28 days (primary outcome) with regdanvimab monoclonal antibody treatment (13%) compared ..
Mar 29
2022
Park et al., Journal of Korean Medical Science, doi:10.3346/jkms.2022.37.e102 Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
79% lower progression (p<0.0001) and 13% shorter hospitalization (p<0.0001). Retrospective propensity score matched analysis of 970 high-risk mild-moderate COVID-19 patients in South Korea, showing regdanvimab significantly reduced risk of disease progression or death by 77% compared to standard care alone. No dea..
Mar 18
2022
Chae et al., Tropical Medicine and Infectious Disease, doi:10.3390/tropicalmed7030051 The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
71% lower mortality (p=1), 64% lower ventilation (p=0.46), and 9% shorter hospitalization (p=0.56). Retrospective 124 hospitalized severe COVID-19 patients receiving oxygen and remdesivir treatment in South Korea. A subgroup of 25 patients also received the monoclonal antibody regdanvimab prior to remdesivir. The regdanvimab subgroup ha..
Mar 8
2022
Choi et al., Infection & Chemotherapy, doi:10.3947/ic.2021.0140 Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study
76% lower need for oxygen therapy (p=0.004). Retrospective 398 hospitalized mild-to-moderate COVID-19 patients in South Korea eligible for regdanvimab treatment. 65 patients received regdanvimab, with significantly lower supplemental oxygen requirements (6.2% vs 20.1% in controls). ..
Feb 2
2022
Streinu-Cercel et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac053 Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients with Mild-to-Moderate Coronavirus Disease 2019
54% lower need for oxygen therapy (p=0.11), 49% lower hospitalization (p=0.2), 49% lower progression (p=0.2), and 35% faster recovery (p=0.003). Phase 2 RCT with 307 outpatients with mild-moderate COVID-19, showing regdanvimab (monoclonal antibody) resulted in a minor decrease in time to negative PCR test (primary endpoint) compared to placebo, which was not statistically signific..
Nov 23
2021
Lee et al., Frontiers in Immunology, doi:10.3389/fimmu.2021.772320 Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
82% lower severe cases (p=0.002), 45% lower need for oxygen therapy (p=0.05), and 8% higher hospital discharge (p=0.001). Retrospective 778 mild COVID-19 patients showing significantly lower progression to severe disease with regdanvimab treatment.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit